Nonaqueous, Mini-Dose Glucagon for Treatment of Mild Hypoglycemia in Adults With Type 1 Diabetes: A Dose-Seeking Study.

Haymond MW, Redondo MJ, McKay S, Cummins MJ, Newswanger B, Kinzell J, Prestrelski S

Diabetes care9 Feb 2016Cited by 34 (Europe PMC)

PMID26861921PMCIDPMC4764034DOI10.2337/dc15-2124PepBankPUB-26861921

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In adults with type 1 diabetes, 75 μg glucagon increased fasting glucose maximally by 33 mg/dL at 60 min from 110 ± 7 mg/dL (P < 0.001).
In plain wordsIn adults with type 1 diabetes, glucagon increased fasting glucose from baseline.
Peptide
Glucagon
Outcome
IncreaseFasting glucose response
Study
n = 12
Outcome group
Glycemic control · Metabolic and weight
Studied dose
75 μg · subcutaneousAs given in this study (human).
Measurements
Maximal increase in fasting glucose
33 mg/dL
75 μg dose, at 60 min
Fasting glucose concentration
110 mg/dL
75 μg dose, baseline (± 7 SE)
Source sentences
Summary
Mean (±SE) fasting glucose concentrations (mg/dL) were 110 ± 7, 110 ± 10, and 109 ± 9 for the 75-, 150-, and 300-μg doses, respectively, increasing maximally at 60 min by 33, 64, and 95 mg/dL (all P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve adults with type 1 diabetes receiving treatment with insulin pumps received subcutaneous doses of 75, 150, and 300 μg of nonaqueous glucagon.
Report a problemFND-2686192101
02HumanNon-randomized trialEfficacy outcome
In adults with type 1 diabetes, 150 μg glucagon increased fasting glucose maximally by 64 mg/dL at 60 min from 110 ± 10 mg/dL (P < 0.001).
In plain wordsIn adults with type 1 diabetes, glucagon increased fasting glucose from baseline.
Peptide
Glucagon
Outcome
IncreaseFasting glucose response
Study
n = 12
Outcome group
Glycemic control · Metabolic and weight
Studied dose
150 μg · subcutaneousAs given in this study (human).
Measurements
Maximal increase in fasting glucose
64 mg/dL
150 μg dose, at 60 min
Fasting glucose concentration
110 mg/dL
150 μg dose, baseline (± 10 SE)
Source sentences
Summary
Mean (±SE) fasting glucose concentrations (mg/dL) were 110 ± 7, 110 ± 10, and 109 ± 9 for the 75-, 150-, and 300-μg doses, respectively, increasing maximally at 60 min by 33, 64, and 95 mg/dL (all P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve adults with type 1 diabetes receiving treatment with insulin pumps received subcutaneous doses of 75, 150, and 300 μg of nonaqueous glucagon.
Report a problemFND-2686192102
03HumanNon-randomized trialEfficacy outcome
In adults with type 1 diabetes, 300 μg glucagon increased fasting glucose maximally by 95 mg/dL at 60 min from 109 ± 9 mg/dL (P < 0.001).
In plain wordsIn adults with type 1 diabetes, glucagon increased fasting glucose from baseline.
Peptide
Glucagon
Outcome
IncreaseFasting glucose response
Study
n = 12
Outcome group
Glycemic control · Metabolic and weight
Studied dose
300 μg · subcutaneousAs given in this study (human).
Measurements
Maximal increase in fasting glucose
95 mg/dL
300 μg dose, at 60 min
Fasting glucose concentration
109 mg/dL
300 μg dose, baseline (± 9 SE)
Source sentences
Summary
Mean (±SE) fasting glucose concentrations (mg/dL) were 110 ± 7, 110 ± 10, and 109 ± 9 for the 75-, 150-, and 300-μg doses, respectively, increasing maximally at 60 min by 33, 64, and 95 mg/dL (all P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve adults with type 1 diabetes receiving treatment with insulin pumps received subcutaneous doses of 75, 150, and 300 μg of nonaqueous glucagon.
Report a problemFND-2686192103
04HumanNon-randomized trialEfficacy outcome
In adults with type 1 diabetes, 75 μg glucagon increased post-insulin glucose maximally by 19 mg/dL from 70 ± 2 mg/dL at 45-60 min (P < 0.02).
In plain wordsIn adults with type 1 diabetes, glucagon increased glucose after insulin administration.
Peptide
Glucagon
Outcome
IncreasePost-insulin glucose response
Study
n = 12
Outcome group
Glycemic control · Metabolic and weight
Studied dose
75 μg · subcutaneousAs given in this study (human).
Measurements
Maximal increase in glucose after glucagon
19 mg/dL
75 μg dose after insulin, at 45-60 min
Post-insulin glucose concentration
70 mg/dL
75 μg dose, before glucagon (± 2 SE)
Source sentences
Summary
The post-insulin administration glucose concentrations were 70 ± 2, 74 ± 5, and 70 ± 2 mg/dL, respectively, with maximal increases of 19, 24, and 43 mg/dL post-glucagon administration (P < 0.02) at 45-60 min.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve adults with type 1 diabetes receiving treatment with insulin pumps received subcutaneous doses of 75, 150, and 300 μg of nonaqueous glucagon.
Report a problemFND-2686192104
05HumanNon-randomized trialEfficacy outcome
In adults with type 1 diabetes, 150 μg glucagon increased post-insulin glucose maximally by 24 mg/dL from 74 ± 5 mg/dL at 45-60 min (P < 0.02).
In plain wordsIn adults with type 1 diabetes, glucagon increased glucose after insulin administration.
Peptide
Glucagon
Outcome
IncreasePost-insulin glucose response
Study
n = 12
Outcome group
Glycemic control · Metabolic and weight
Studied dose
150 μg · subcutaneousAs given in this study (human).
Measurements
Maximal increase in glucose after glucagon
24 mg/dL
150 μg dose after insulin, at 45-60 min
Post-insulin glucose concentration
74 mg/dL
150 μg dose, before glucagon (± 5 SE)
Source sentences
Summary
The post-insulin administration glucose concentrations were 70 ± 2, 74 ± 5, and 70 ± 2 mg/dL, respectively, with maximal increases of 19, 24, and 43 mg/dL post-glucagon administration (P < 0.02) at 45-60 min.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve adults with type 1 diabetes receiving treatment with insulin pumps received subcutaneous doses of 75, 150, and 300 μg of nonaqueous glucagon.
Report a problemFND-2686192105
06HumanNon-randomized trialEfficacy outcome
In adults with type 1 diabetes, 300 μg glucagon increased post-insulin glucose maximally by 43 mg/dL from 70 ± 2 mg/dL at 45-60 min (P < 0.02).
In plain wordsIn adults with type 1 diabetes, glucagon increased glucose after insulin administration.
Peptide
Glucagon
Outcome
IncreasePost-insulin glucose response
Study
n = 12
Outcome group
Glycemic control · Metabolic and weight
Studied dose
300 μg · subcutaneousAs given in this study (human).
Measurements
Maximal increase in glucose after glucagon
43 mg/dL
300 μg dose after insulin, at 45-60 min
Post-insulin glucose concentration
70 mg/dL
300 μg dose, before glucagon (± 2 SE)
Source sentences
Summary
The post-insulin administration glucose concentrations were 70 ± 2, 74 ± 5, and 70 ± 2 mg/dL, respectively, with maximal increases of 19, 24, and 43 mg/dL post-glucagon administration (P < 0.02) at 45-60 min.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve adults with type 1 diabetes receiving treatment with insulin pumps received subcutaneous doses of 75, 150, and 300 μg of nonaqueous glucagon.
Report a problemFND-2686192106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT02081014

Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes

Xeris Pharmaceuticalsn = 13Mar 2014 to Nov 2014

Hypoglycemia

Trial page ClinicalTrials.govUpdated 5 Apr 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.